Gelesis Holdings (Gelesis Holdings) EV-to-EBIT : 0.00 (As of Jun. 22, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gelesis Holdings's Enterprise Value is $0.00 Mil. Gelesis Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-47.77 Mil. Therefore, Gelesis Holdings's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Gelesis Holdings's EV-to-EBIT or its related term are showing as below:

GLSWQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.67 Med: -1.47 Max: -1.13
Current: -1.13

During the past 2 years, the highest EV-to-EBIT of Gelesis Holdings was -1.13. The lowest was -5.67. And the median was -1.47.

GLSWQ's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.76 vs GLSWQ: -1.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Gelesis Holdings's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil. Gelesis Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-47.77 Mil. Gelesis Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.

Gelesis Holdings EV-to-EBIT Historical Data

The historical data trend for Gelesis Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings EV-to-EBIT Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

EV-to-EBIT

-1.63

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EV-to-EBIT	Get a 7-Day Free Trial					-1.98	-2.42	-1.63	-1.56	-1.46

Competitive Comparison of Gelesis Holdings's EV-to-EBIT

For the Biotechnology subindustry, Gelesis Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's EV-to-EBIT falls into.

Gelesis Holdings EV-to-EBIT Calculation

Gelesis Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-47.769
	=	0.00

Gelesis Holdings's current Enterprise Value is $0.00 Mil.
Gelesis Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.77 Mil.

Gelesis Holdings (OTCPK:GLSWQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Gelesis Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	-47.769	/	0
	=	%

Gelesis Holdings's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil.
Gelesis Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.77 Mil.

Gelesis Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSWQ) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.